Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Process Engineer (or Research Associate) - Fermentation & DSP
jobs
Process Engineer (or Research Associate) - Fermentation & DSPFebruary 6, 2026
Process Development Lead
jobs
Process Development LeadFebruary 6, 2026
Nasdaq's 'Amplify Spotlight'
heltzeninvestorpress clippingsvideo
Nasdaq: Michael B. Spector interviews CEO HeltzenFebruary 5, 2026
Pharma-grade NCT ready for partner testing
press releaseinvestornutraceuticalsscience
eXoZymes advancing commercial readiness with profound production metrics on initial NCT pilot runJanuary 29, 2026
Capital Markets Advisor, Sanjeev Srivastava, interviewed by Maxine Hoover
investorpress clippingsvideo
Beryl Elites: Interview with Capital Markets Advisor, Sanjeev SrivastavaJanuary 8, 2026
CEO Heltzen interviewed by Maxine Hoover at the Beryl Elites’ Investment Conference in New York City
heltzeninvestorpress clippingsvideo
Beryl Elites: What is Artificial Evolution - an interview with CEO HeltzenJanuary 7, 2026
IBT: AI meets enzymes
investornutraceuticalsmedicinepress clippings
International Business Times: AI meets enzymes - eXoZymes enables high-yield production of compounds previously impossible to makeDecember 17, 2025
CEO Michael Heltzen at the Beryl Elite's 'AI in Life Sciences' panel
heltzeninvestorpress clippings
Beryl Elites: AI's Billion-dollar Bet on Life Sciences - From Drug Discovery to Patient Impact (panel)December 15, 2025
100× scale-up of NCT production achieved
press releaseinvestornutraceuticalsmedicine
eXoZymes achieves 100× scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversionDecember 11, 2025
Vanity Fair: Inside NCTx - How A Rare Plant-Derived Molecule Is Turning Fat Into A Boost Of Energy
nutraceuticalsmedicinepress clippings
Vanity Fair: Inside NCTx - How A Rare Plant-Derived Molecule Is Turning Fat Into A Boost Of EnergyNovember 26, 2025
Previous page
Page 1 of 11
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark